Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V5JH
|
|||
| Former ID |
DIB013179
|
|||
| Drug Name |
ALT-801
|
|||
| Synonyms |
ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor
Click to Show/Hide
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 2 | [1] | |
| Bladder cancer [ICD-11: 2C94; ICD-9: 188] | Phase 2 | [2] | ||
| Non-muscle invasive bladder cancer [ICD-11: 2C94; ICD-10: C67, C67.9; ICD-9: 188] | Phase 1/2 | [3] | ||
| Company |
Altor bioscience
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15;17(24):7765-75. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.